Vitiligo

Vitiligo is an acquired skin disorder characterized by localized or generalized loss of skin pigmentation due to the destruction of melanocytes, the cells that produce melanin. The condition appears as white patches of skin of varying shapes and sizes, caused by the lack of pigmentation. Vitiligo can affect any part of the body, including the face, arms, legs, and hair, and generally causes no physical discomfort, but can have a significant psychological impact on the patient. Epidemiological studies suggest that it has an incidence of about 0.5% to 2% in the general population, with symptoms often appearing at a young age.

History of the disease and interesting historical facts

The history of vitiligo goes back to ancient times. The first mentions of the disease can be found in medical texts of Ancient Egypt, where it was described under the name "lichen alba". In India, monuments of art and literature indicate that vitiligo was known as early as the 4th century BC. In European medicine, this disease also had its uses; in particular, Hippocrates discussed various skin diseases, including vitiligo, in his works. However, various mythological interpretations can be traced in the history of the disease, including the belief that vitiligo is the result of improper behavior or excessive passion. Modern research provides a better understanding of the mechanism of pathology and its true causes.

Epidemiology

The epidemiology of vitiligo indicates that the disease affects people of all races and ethnicities, although its manifestations may vary depending on the skin type. According to the World Health Organization, the prevalence of vitiligo varies from 0.5% to 2% in different populations. In addition, statistical studies show that vitiligo is most often observed in patients between the ages of 10 and 30 years, with women being slightly more susceptible to the disease than men. It is important to note that vitiligo can occur in any population group, but individual races and ethnic groups may have different levels of severity and patterns of distribution.

Genetic predisposition to this disease

Genetic studies show that a patient with vitiligo has a 2-5% chance that the disease will manifest in close relatives. Some genes associated with the immune response and skin pigmentation (for example, genes of the HLA family) play an important role in the pathogenesis of vitiligo. The study of genetic predisposition allows us to identify mutations in genes such as TYR (tyrosinase), TRP-1 and TRP-2, which are responsible for the synthesis of melanin. In parallel, there is also a link between vitiligo and other autoimmune diseases, such as thyroid dysfunction and pernicious anemia, which allows us to consider in more detail the autoimmune mechanisms associated with the development of the disease.

Risk factors for the development of this disease

There are a number of risk factors that can influence the development of vitiligo, including:

• Physical factors: sunburn, exposure to chemicals, mechanical trauma to the skin.
• Chemical factors: contact with certain toxic substances such as phenols and para-aminobenzoic acid.
• Psycho-emotional factors: stress and emotional disorders, which can lead to activation of the autoimmune process.
• Other medical conditions: presence of concomitant diseases such as diabetes, hypothyroidism.

Having one or more of these factors may increase the likelihood of developing vitiligo, but their exact interaction with genetic predisposition is still a subject of active research.

Diagnosis of this disease

Diagnosis of vitiligo is based on clinical examination and may include:

• The main symptoms are the appearance of white spots on the skin, no flaking, itching or pain in the affected area.
• Laboratory tests: blood tests to detect associated autoimmune diseases.
• Radiological examinations: in rare cases, ultrasound or MRI may be required to rule out other pathologies.
• Other types of diagnostics: dermatoscopy to assess the condition of the skin and determine the boundaries of lesions.
• Differential diagnosis: exclusion of other skin diseases such as lichen, psoriasis and eczema.

Thus, the diagnosis of vitiligo requires a comprehensive approach and analysis of various data to exclude other possible diagnoses.

Treatment

Treatment of vitiligo can be varied and should be individualized depending on the severity of the disease and the age of the patient. The main approaches are:

• General treatment: Use sunscreen to protect skin areas from sunlight.
• Pharmacological treatment: use of corticosteroid creams and ointments, as well as medications that stimulate the restoration of pigmentation, such as psoralens.
• Surgical treatment: in cases of severe forms of the disease, skin transplantation or micropigmentation may be possible.
• Other treatments include phototherapy using UVB or PUVA therapy, and the use of immunosuppressants to control autoimmune processes.

Each treatment method requires the supervision of a physician and is based on a thorough assessment of the clinical situation.

List of medications used to treat this disease

Some of the most common medications used to treat vitiligo include:

• Topical corticosteroids (eg, hydrocortisone, betamethasone).
• Psoralens (eg, methoxsalen).
• Immunomodulators (eg, tacrolimus).
• Photosensitizers for combination treatment with phototherapy.
• Creams and ointments with vitamin D.

Proper use of these medications under the supervision of a dermatologist can help manage the symptoms of the disease and improve the patient's quality of life.

Disease monitoring

Monitoring vitiligo involves regular examinations by a dermatologist to assess the dynamics of the condition:

• Control stages: regular checks of the skin to detect new areas of pigmentation or the spread of existing ones.
• Prognosis: In most cases, vitiligo has a benign course, but requires constant monitoring due to the possible development of concomitant autoimmune diseases.
• Complications: psychoemotional disorders, social stigma, decreased quality of life due to visible skin lesions.

It is important to take into account that treatment and monitoring should be aimed not only at physical manifestations, but also at the psychological aspect of the patient's condition.

Age-related features of the disease

Vitiligo can occur in people of any age, but its course and response to treatment may vary:

• In children: Vitiligo is often diagnosed at an early age, and psychological stress becomes the main problem.
• In adolescents: the course of the disease may be associated with changes in hormonal levels, which sometimes leads to a more pronounced spread.
• In adults: manifestations are often more widespread, and other autoimmune diseases may join in.
• In the elderly: decreased latent immune function may increase the likelihood of disease progression.

Thus, the approach to treatment and monitoring depends on the patient's age group.

Questions and Answers

• What causes vitiligo? Vitiligo is generally considered to be an autoimmune disease, in which the immune system attacks the melanocytes responsible for pigmentation. This may be due to genetic predisposition and exposure to external factors.
• Can vitiligo be cured? There is currently no complete cure for vitiligo, but there are treatments that can help restore pigmentation to the affected areas.
• How does vitiligo affect quality of life? Vitiligo can have a significant impact on the patient's psychological state, causing feelings of shame and low self-esteem. It is important to seek psychological support.
• Is sun exposure safe for people with vitiligo? Because people with vitiligo lack pigmentation in the affected areas, they are more susceptible to sunburn, so sunscreen must be used.
• Does stress affect the development of vitiligo? Yes, stress can aggravate the condition and activate the progression of vitiligo, so stress management is an important aspect of treatment.